Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From AmerisourceBergen Corporation.
How To Develop A Patient-First Strategy For CGT Commercialization
Many new drug commercialization decisions need to happen early in the clinical development of a therapy, and cell and gene treatments are no different. As Amerisource Bergen’s Lung-I Cheng tells In Vivo, creating a patient-first blueprint is the best place to start.
Walgreens And CVS Agree To Opioid Settlements, But States Waiting To See Details
As states weigh their options, the history of past settlements will be a factor. One state signed onto the settlement with the distributors but opted out of the deal with J&J, netting it millions more, and with faster payment, than it would have received under the national settlement.
Teva Wins Support For Nationwide Opioid Settlement With Bigger Cash Offer
Teva to pay $4.25bn over 13 years under agreement in principle with 12 state attorneys general, Native American tribes and plaintiffs’ lawyers. Previous settlement offer provided mostly medication. Deal is contingent on governments signing on and Allergan inking settlement.
Manufacturer Engagement In ICER Reviews Widespread; How Much It Helps Is Less Clear
Tufts study evaluates the extent and impact of manufacturer engagement with the Institute for Clinical and Economic Review while recent survey by Xcenda finds payer reliance on ICER reports is growing.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.